Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

PLX

Strong BuyFull HouseFLAG

Protalix BioTherapeutics, Inc. · Healthcare · United States · $205M · Avg Vol: $2M/d

97
StockRank
Get insider-trade alerts
Q
75
V
67
M
65
P/E (TTM)
11.6x
ROE
31.2%
D/E
0.1x
Dividend %
—
Dir. Trades · 180d
None →
Buybacks · 180d
None →
AI CONVICTION THESIS

The stock meets quantitative eligibility requirements but lacks any positive in-house regulatory signals or catalyst-driven revisions. It remains in the default FLAG status due to insufficient conviction evidence.

COMPANY DESCRIPTION

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue47.6M65.5M53.4M52.7M3.5%80.6M79.8M68.2M13.7%
EPS-0.310.120.04-0.08-66.7%0.230.190.0611.2%
Shares53.8M73.0M75.9M80.4M+49.5%80.6M———
Debt33.5M26.3M5.5M8.3M-37.1%9.2M———
Equity-10.6M33.6M43.2M48.2M19.9%————
Op CF-25.0M-1.3M8.7M-12.0M—9.9M———
Inv CF-5.0M-16.7M4.2M-2.4M—————
Fin CF8.2M24.7M-16.8M9.3M—————
Loading 1Y...
PRICE (1Y)+20.3%
2.222.352.482.602.73Jul 30Aug 20Sep 10
SMA 50SMA 200

Close
$2.73
RSI (14)
81.8
52W High
$3.19
From 52W High
0.9%

SCORE BREAKDOWN

Quality
75
ROIC
37.3%97.7
ROE
31.2%95.0
GP/Assets
44.8%82.6
Op. Margin
23.5%87.1
FCF/Assets
15.8%94.0
Piotroski
10.8
Int. Cover
13.5x66.1
D/E Ratio
0.13x58.8
Current Ratio
2.94x54.4
Value
67
P/E (TTM)
11.6x84.7
EV/EBITDA
7.2x83.3
P/FCF
15.7x68.8
P/B
3.2x43.7
P/S
2.7x60.5
Div Yield
—N/A
Momentum
65
52W High %
86%74.3
RS 6M
-18%38.7
SMA 50/200
1.07x71.2
EPS Rev 4W
0.0%34.5
EPS Rev 12W
—N/A
EPS Improve
+170%84.5
Q Growth
2203%99.2

FUNDAMENTALS

Market Cap
$205M
P/E (Forward)
4.3x
Gross Margin
45.8%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PLX are excluded.

TickerCompanyMkt CapStockRankSignal
PLXProtalix BioTherapeutics, Inc.(you)$205M97Strong Buy
1521.HKFrontage Holdings Corporation$310M93Strong Buy
ORMPOramed Pharmaceuticals Inc.$209M80Strong Buy
PBYIPuma Biotechnology, Inc.$468M98Strong Buy
QTTBQ32 Bio Inc.$447M89Strong Buy
CRMDCorMedix Inc.$647M98Strong Buy
ZVRAZevra Therapeutics, Inc.$687M91Strong Buy
RIGLRigel Pharmaceuticals, Inc.$868M99Strong Buy
AGENAgenus Inc.$345M75Buy
ICCCImmuCell Corporation$90M73Buy

Peer medians: ROE -30.8% · P/E 27.1x · Gross margin 58.3%

Protalix BioTherapeutics, Inc. (PLX): Stock Score Summary

Protalix BioTherapeutics, Inc. (PLX) has a MoatMap StockRank of 97/100 based on Quality (75/100), Value (67/100), and Momentum (65/100) factor scores. The current signal is STRONG BUY. The stock meets quantitative eligibility requirements but lacks any positive in-house regulatory signals or catalyst-driven revisions. It remains in the default FLAG status due to insufficient conviction evidence.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.

Key Financial Metrics

Price$2.73
Market Cap$205M
P/E (TTM)11.61
P/E (Forward)4.31
Price/Book3.20
Return on Equity31.2%
Return on Invested Capital37.3%
Debt/Equity0.13x
Gross Margin45.8%
Operating Margin23.5%
Revenue Growth27.1%
Free Cash Flow$13M

Protalix BioTherapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Protalix BioTherapeutics, Inc.’s (PLX) StockRank?
MoatMap’s StockRank for Protalix BioTherapeutics, Inc. (PLX) is 97/100, with a Strong Buy signal. It is a composite of Quality (75), Value (67), and Momentum (65) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Protalix BioTherapeutics, Inc. have an economic moat?
Protalix BioTherapeutics, Inc. (PLX) has a Quality factor score of 75/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Protalix BioTherapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Protalix BioTherapeutics, Inc. (PLX) is Strong Buy, based on a StockRank of 97/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Protalix BioTherapeutics, Inc. in?
Protalix BioTherapeutics, Inc. (PLX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksPLX deep dive reportAI ChampionsHow we score stocksSense-check another stock